Collagen & Peptide NutritionNutrition and collagen guides

Nutrition guide

Scientists uncover why brain damage continues after stroke

Every stroke begins with a sudden interruption of blood flow in the brain. But what happens afterward—why neurons continue to lose function and die over the following days—has remained one of the most important unanswered questions in neuroscience. A research

Every stroke begins with a sudden interruption of blood flow in the brain. But what happens afterward—why neurons continue to lose function and die over the following days—has remained one of the most important unanswered questions in neuroscience.

A research team led by Director C. Justin LEE at the Center for Memory and Glioscience within the Institute for Basic Science (IBS), in collaboration with Professor RYU Seungjun of Eulji University, has now uncovered a previously unknown mechanism that drives this delayed brain damage. Their findings show that stroke is not only caused by the initial loss of blood flow, but also by a chain reaction within the brain that unfolds over time.

In the brain, neurons rely on astrocytes—star-shaped support cells that help maintain the chemical environment and protect neural circuits. After a stroke, astrocytes rapidly respond to injury by forming a structure known as the glial barrier, which has long been thought to protect surrounding tissue. However, the new study shows that this response can take a harmful turn.

The researchers found that immediately after a stroke, levels of hydrogen peroxide (H₂O₂), a reactive oxygen molecule, rise sharply in the affected region. This surge triggers astrocytes to undergo a metabolic shift and begin producing large amounts of type I collagen, a structural protein rarely found in the healthy brain. As collagen accumulates, it becomes incorporated into the glial barrier, creating a dense environment that actively promotes neuronal death rather than preventing it.

To confirm that collagen plays a direct role in this process, the team first blocked its production by silencing a key gene in astrocytes. When collagen synthesis was suppressed, neuronal death was significantly reduced, demonstrating that this pathway is not merely associated with damage but is a major driver of it. Further experiments showed that collagen can act as a signaling molecule, activating receptors on neurons and triggering a slow degenerative process that unfolds over several days.

We elucidated, at the molecular and cellular levels, the mechanism by which reactive oxygen species induce collagen synthesis in astrocytes. This finding provides a crucial clue for understanding the diverse causes of neuronal death and may serve as a foundation for developing treatments not only for stroke, but also for neurodegenerative diseases such as dementia and Parkinson's disease." Dr. Boyoung Lee, Study Co-Corresponding Author and Research Fellow/ Principal Investigator, Institute for Basic Science

The researchers then asked whether this damaging cascade could be stopped at an earlier stage. Instead of targeting collagen directly, they tested a newly developed drug called KDS12025, which reduces hydrogen peroxide levels and prevents the entire process from being triggered. In mouse models of stroke, the treatment reduced collagen accumulation, prevented the formation of the glial barrier, preserved neuronal function, and restored motor performance.

Most strikingly, the drug remained effective even when administered up to two days after stroke onset. This finding is particularly significant because current stroke treatments are typically limited to a narrow "golden time" window of only a few hours. Extending this window from hours to days suggests that brain damage previously thought to be irreversible may still be preventable.

To examine whether these effects could translate to more human-like systems, the team applied the same approach to a stroke model in monkeys. Untreated animals were unable to grasp food due to paralysis, while monkeys treated with KDS12025 regained motor function and successfully grasped food in all 10 out of 10 attempts during behavioral testing. The treated animals also showed reduced brain damage and improved overall neurological function.

Co-corresponding author Professor RYU Seungjun added, "We propose hydrogen peroxide and collagen as novel therapeutic targets for stroke. By demonstrating efficacy in a non-human primate model rather than only in cells or small animals, we anticipate a substantial reduction in the time required for clinical translation and new hope for patients."

These findings suggest that stroke is not simply a one-time event, but a progressive biological process driven by interactions between different cell types in the brain. By identifying hydrogen peroxide-induced collagen production in astrocytes as a key step in this process, the study provides a new framework for understanding how brain damage develops—and how it might be stopped.

Beyond stroke, the mechanism uncovered in this work may also have broader implications for neurological disorders involving oxidative stress and tissue remodeling, including neurodegenerative diseases. The results point toward a new therapeutic strategy: intervening not only at the moment of stroke, but during the critical period afterward when brain cells are still at risk but potentially recoverable.

Corresponding author Director C. Justin LEE (IBS) remarked, "By establishing a 'one-stop research system' that integrates the entire process—from basic research to drug development and preclinical validation—we have succeeded not only in identifying the root cause of stroke but also in presenting a concrete therapeutic strategy. We will continue to pursue basic science research that directly benefits humanity and society, as exemplified by KDS12025."

Lee, J.-H., et al (2026) Oxidative stress-induced astrocytic collagen biosynthesis drives glial barrier formation and neuronal death in ischemic stroke. Cell Metabolism. DOI: 10.1016/j.cmet.2026.04.001. https://www.sciencedirect.com/science/article/pii/S1550413126001397.

SUPPLEMENTAL FIELD FILE

Notes to carry forward.

Source-derived references linked through this guide’s public topic markers.

03
QUESTIONS FROM THE TRAIL

Related questions

Q01What have you learned about how your human muscle platform compares with traditional animal models?

Drug development remains slow, expensive, and heavily reliant on animal models that do not always predict human outcomes accurately. Our human muscle platforms are designed to help bridge that gap by providing more human-relevant data earlier in the development process. By improving the predictive power of preclinical testing, our models have the potential to make drug development faster, more efficient, and ultimately more successful. Our ambition is for them to significantly shorten development timelines and increase the likelihood that new therapies will succeed in the clinic. In studies conducted with industry partners, compounds known to induce muscle toxicity in animal models have also produced comparable toxic effects in our human-derived systems. This provides confidence that the platform can identify clinically relevant responses while offering a more direct representation of human tissue biology. Ultimately, we believe human tissues should be used to predict human outcomes.

Source trail · www.news-medical.net →
Q02Where is collagen found?

In nature, collagen is found exclusively in animals, especially in the flesh and connective tissues of mammals. Collagen is a part of the connective tissue that in the skin helps in firmness, suppleness and constant renewal of skin cells. Collagen is vital for skin elasticity. Ligaments are another type of connective tissue that attach two bones and consequently hold the joints together. Tendons are similar but different type of tissue that attach the muscles to the bones. All of these tissues, the bones, ligaments, tendons and the skeletal muscles themselves, are made up of proteins. One of the most predominant proteins is called collagen. Collagen is the main component of connective tissue, and is the most abundant protein in mammals, making up about 25% to 35% of the whole-body protein content.

Source trail · www.news-medical.net →
Q03What is AHCC?

A Japanese firm, Amino Up Co., Ltd., produces a standardized extract of the mycelia of the cultured mushroom Lentinula edodes. AHCC has shown the ability to increase dendritic cell numbers in the blood, enhance virus elimination, increase influenza antibody titers post-vaccination, and reduce cancer recurrences after liver tumor resection. In the last case, its use was also associated with a reduction in cirrhosis odds compared to the group that did not take this agent. This prompted the current study, where AHCC was examined for its potential to prevent the progression of liver fibrosis by inhibiting hepatic stellate cell (HSC) activation.

Source trail · www.news-medical.net →